You are here

Topic 368: Biotherapy of Brain Tumors by Radioiodinated SapC-DOPS Nanovesicles

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 261201700037C-3-0-0
Agency Tracking Number: N43CA170037
Amount: $50,007.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2016
Award Year: 2018
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
833 LINCOLN AVE, UNIT 9
WEST CHESTER, PA 19380-4471
United States
DUNS: 928315084
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Brian D Gray
 (610) 738-7938
 briangray@mtarget.com
Business Contact
 Brian D Gray
Phone: (610) 738-7938
Email: briangray@mtarget.com
Research Institution
N/A
Abstract

There is an urgent need for more effective drug delivery agents for treatment of brain tumors, which are among the most aggressive and intractable cancers. SapC-DOPS, a nanovesicle composed of saposin C (SapC) coupled to dioleoylphosphatidylserine (DOPS), has proven tumor targeting properties, which include crossing the blood-brain tumor barrier and binding the lipid tumor marker, extracellular phosphatidylserine (PS). It also exhibits antitumor activities in preclinical glioblastoma (GBM) models. We hypothesize that endowing SapC-DOPS nanovesicles with a radiolabeled lipophilic reporter will create a novel agent with superior efficacy for targeted radionuclide therapy (TRT) of GBMs. Treatment options for GBMs are very limited, and standard therapies with radiation and/or chemotherapy provide only modest survival benefits with potential deleterious effects. To address these issues, we propose to create a novel cancer-selective, targeted radiolabeled SapC-DOPS for TRT of GBMs. A unique advantage of MTTI's approach lies in the feedforward therapeutic mechanism of the novel compound: radiation exposure is known to increase PS externalization in tumor cells, thus leading to enhanced anticancer effects by PS-targeted SapC-DOPS nanovesicles. This proposal is backed by extensive, published and unpublished, preliminary data, the FDA Orphan Drug designation of SapC-DOPS, and an ongoing clinical phase I trial.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government